Cardiovascular Surgery

This channel includes news and new technology innovations in cardiac surgery. This includes coronary artery bypass grafts (CABG), open chest structural heart surgical repairs and valve replacements, heart transplants, and placement of extracorporeal membrane oxygenation (ECMO), left ventricular assist devices (LVAD) and artificial hearts.

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.

News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart...
In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart.  #ACC21 #ACC2021

In the LAAOS III trial, surgeons could seal off the LAA during the open heart procedure using sutures, staples or approved closure devices. The image shows a SentraHeart lasso type LAA occluder about to seal off the LAA from the outside of the heart. 

News | Left Atrial Appendage (LAA) Occluders | May 15, 2021
May 15, 2021 — Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib),...
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting...
The Transmedics Organ Care System (OCS) Heart, or “Heart in a Box,” enables transplant surgeons to travel to much farther destinations to procure transplant hearts by acting as a miniature intensive care unit that keeps the heart alive.

The Transmedics Organ Care System (OCS) Heart, or “Heart in a Box,” enables transplant surgeons to travel to much farther destinations to procure transplant hearts by acting as a miniature intensive care unit that keeps the heart alive.

News | Cardiovascular Surgery | April 05, 2021
April 5, 2021 — Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to...
Videos | Ventricular Assist Devices (VAD) | March 22, 2021
Surgeons at Penn State Heart and Vascular Institute were the second group in the nation to implant a newly-designed...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the...
LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

News | Heart Failure | March 02, 2021
March 2, 2021 — Penn State Health Milton S. Hershey Medical Center became the second hospital in the nation to implant...
Medtronic Recalls HVAD Pump Implant Kits After 2 Deaths and 19 Serious Injuries
News | Ventricular Assist Devices (VAD) | March 01, 2021
March 1, 2021 — Medtronic is recalling the HeartWare Ventricular Assist Device (HVAD) Pump Implant Kit because the left...
Two types of cardiac output monitoring. Left, is the lithium dilution technology is used to monitor and optimize hemodynamics. Show here is the LiDCOplus technology. Right, an example of an invasive pulmonary artery (PA) catheter used for invasive right heart hemodynamic monitoring.

Two types of cardiac output monitoring. Left, is the lithium dilution technology is used to monitor and optimize hemodynamics. Show here is the LiDCOplus technology. Right, an example of an invasive pulmonary artery (PA) catheter used for right heart hemodynamic monitoring.

Feature | Hemodynamic Monitoring Systems | February 23, 2021
The overall trend in the cardiac output monitoring market is a movement toward noninvasive or minimally monitoring...
The Carmat artificial heart
News | Artificial Heart | February 10, 2021
February 10, 2021 - The U.S. Food and Drug Administration (FDA) has granted artificial heart developer Carmat approval...
The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.

News | Heart Failure | January 13, 2021
January 13, 2021 — FineHeart, a preclinical-stage medical device company developing a novel left ventricular assist...
A coronary artery bypass graft (CABG) procedure where blockages in the coronaries are bypassed using a blood vessel harvested from elsewhere in the body and connected to the vessel past the blockage to supply blood to the heart. A new study shows better outcomes seen in multiple vs. single coronary artery bypass grafts (CABG) in men and sex appears to play a role in mortality. Getty Images

A coronary artery bypass graft (CABG) procedure where blockages in the coronaries are bypassed using a blood vessel harvested from elsewhere in the body and connected to the vessel past the blockage to supply blood to the heart. A new study shows better outcomes seen in multiple vs. single coronary artery bypass grafts (CABG) in men and sex appears to play a role in mortality. Getty Images

News | Womens Cardiovascular Health | January 06, 2021
January 6, 2020 — A new Weill Cornell Medicine found the risk of dying seven years after coronary artery bypass graft (...
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an...
CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

News | Heart Failure | December 02, 2020
December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage policies...
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News | November 18, 2020
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial...